No, Xefo Rapid (lornoxicam) is NOT a selective COX-2 inhibitor
Lornoxicam is a nonselective NSAID that inhibits both COX-1 and COX-2 enzymes in a balanced manner. This distinguishes it from selective COX-2 inhibitors (coxibs) like celecoxib, rofecoxib, or etoricoxib 1.
Mechanism of Action
Lornoxicam demonstrates balanced inhibition of both COX-1 and COX-2 with nearly equal potency. Research shows it has an IC50 of 0.005 μM for COX-1 and 0.008 μM for COX-2 in intact human cells, making it one of the most potent balanced COX inhibitors tested 2. This equipotent inhibition of both isoforms places it firmly in the category of traditional nonselective NSAIDs 1.
Clinical Classification
According to consensus guidelines, NSAIDs are classified into two main categories 1:
- Nonselective NSAIDs (nsNSAIDs): Reversibly inhibit both COX-1 and COX-2 activity
- Coxibs (selective NSAIDs): Reversibly inhibit COX-2 more than COX-1 due to higher affinity for COX-2
Lornoxicam belongs to the first category as a nonselective NSAID.
Clinical Implications
Gastrointestinal Risk
Because lornoxicam inhibits COX-1 (which produces gastroprotective prostaglandins), it carries the typical GI risks associated with nonselective NSAIDs 1, 3. However, pooled data from 60 studies showed that lornoxicam had a reduced risk of GI adverse events compared to other NSAIDs (relative risk 0.78,95% CI: 0.64-0.96) 4, though GI events still occurred in 14% of patients versus 8% with placebo.
Cardiovascular Considerations
Unlike selective COX-2 inhibitors that preferentially reduce prostacyclin while sparing thromboxane production, lornoxicam's balanced COX inhibition theoretically provides a more favorable cardiovascular profile 5, 6. The cardiovascular risk with COX-2 selective agents is proportional to their degree of COX-2 selectivity 7, 5.
Appropriate Use
When prescribing lornoxicam, apply the same precautions as with other nonselective NSAIDs 8:
- Consider GI prophylaxis with a proton pump inhibitor in high-risk patients (history of ulcers, age ≥75 years, concurrent aspirin use) 8, 9
- Avoid in patients with chronic kidney disease stage IV-V, active peptic ulcer disease, or heart failure 8, 10
- Monitor renal function, blood pressure, and cardiovascular status, especially in elderly patients 10
- Use the lowest effective dose for the shortest duration necessary 7
Common Pitfall
Do not assume that lornoxicam has the same GI safety profile as selective COX-2 inhibitors when used alone. While it may have somewhat better GI tolerability than some other nonselective NSAIDs 4, it still requires the same risk mitigation strategies as traditional NSAIDs, particularly regarding gastroprotection in high-risk patients 8, 9.